AU4328399A - Nucleic acid-cobalamin complexes and their use in gene therapy - Google Patents
Nucleic acid-cobalamin complexes and their use in gene therapyInfo
- Publication number
- AU4328399A AU4328399A AU43283/99A AU4328399A AU4328399A AU 4328399 A AU4328399 A AU 4328399A AU 43283/99 A AU43283/99 A AU 43283/99A AU 4328399 A AU4328399 A AU 4328399A AU 4328399 A AU4328399 A AU 4328399A
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- gene therapy
- cobalamin
- complexes
- cobalamin complexes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8929198P | 1998-06-15 | 1998-06-15 | |
US60089291 | 1998-06-15 | ||
PCT/US1999/012236 WO1999065529A1 (en) | 1998-06-15 | 1999-06-02 | Nucleic acid-cobalamin complexes and their use in gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4328399A true AU4328399A (en) | 2000-01-05 |
Family
ID=22216811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU43283/99A Abandoned AU4328399A (en) | 1998-06-15 | 1999-06-02 | Nucleic acid-cobalamin complexes and their use in gene therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4328399A (en) |
WO (1) | WO1999065529A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ071299A0 (en) * | 1999-06-02 | 1999-06-24 | Access Pharmaceuticals Australia Pty Limited | Vitamin directed dual targeting therapy |
US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
CN1301718A (en) * | 1999-12-27 | 2001-07-04 | 上海博德基因开发有限公司 | New polypeptide-cobalamin binding protein 10 and polynucleotide coding such polypeptide |
AU2002258546B2 (en) * | 2001-03-16 | 2006-09-07 | University Of Utah Research Foundation | Fluorescent cobalamins and uses thereof |
AU2002362312A1 (en) * | 2001-09-17 | 2003-04-01 | Mayo Foundation For Medical Education And Research | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
JP3296817B2 (en) * | 1991-04-02 | 2002-07-02 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | Oral distribution system suitable for fine particles |
AU2916292A (en) * | 1991-10-24 | 1993-05-21 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
-
1999
- 1999-06-02 WO PCT/US1999/012236 patent/WO1999065529A1/en active Application Filing
- 1999-06-02 AU AU43283/99A patent/AU4328399A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999065529A1 (en) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9801216A3 (en) | Dna molecules, preparation thereof and use thereof in gene therapy | |
AU7499198A (en) | Gene expression profiles in normal and cancer cells | |
AU1606897A (en) | Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy | |
AU3560399A (en) | Tumor associated nucleic acids and uses therefor | |
AU1922301A (en) | Differential gene expression in cancer | |
AU5691699A (en) | Human genes differentially expressed in colorectal cancer | |
AU8536998A (en) | Regulatory sequences involved in hypoxia regulated gene expression and uses thereof | |
AU5918098A (en) | Non-immunogenic prodrugs and selectable markers for use in gene therapy | |
HUP0104825A3 (en) | Genes and proteins, and their use | |
IL136826A0 (en) | Essential bacterial genes and their use | |
AU3979395A (en) | DNA sequences and their use | |
AU1520499A (en) | Essential fungal genes and their use | |
AU1598599A (en) | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases | |
AU2238499A (en) | Androgen-metabolic gene mutations and prostate cancer risk | |
AU4328399A (en) | Nucleic acid-cobalamin complexes and their use in gene therapy | |
IL136005A0 (en) | Essential bacterial genes and their use | |
AU2529799A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
IL112993A0 (en) | Recombinant niruses, their preparation and their use in gene therapy | |
PL351027A1 (en) | Outer surface proteins, their genes, and their use | |
AU5871898A (en) | Microparticles and their use in cancer treatment | |
AU4860299A (en) | (zap-3) tumor associated genes and their uses | |
AU1926699A (en) | Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis | |
AU3349997A (en) | Reg gene expression in cancer tissue | |
AU6149600A (en) | Novel vector complexes and their use in gene therapy | |
AU5764399A (en) | Antigen-presenting cells and their use in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |